Barry E. Toyonaga
Profile
Prior to becoming an Executive Director, Dr. Toyonaga held advisory positions on Ventana's Executive Advisory Committee and Scientific Advisory Board.
For the past few years, he has provided consulting services and interim executive/general management support to the biotech industry – from startups to business and capital support providers – as they relate to the business management of R&D, i.e.
business and technology diligence, fund raising, corporate and business development, IP strategy, real estate and TI strategies, and issues related to the handling/disposal of biological, chemical and radioactive hazardous materials.
Prior to that Dr. Toyonaga held senior management positions with responsibilities for the business management of R&D at Protein Design Labs, Inc. and within the Johnson & Johnson organization.
While at J&J, he was accepted as a Visiting Research Scientist at The Scripps Research Institute (La Jolla, CA) and established the J&J Laboratories at Scripps.
Before that he was a Visiting Scientist at the California Institute of Technology (Pasadena, CA), Yale University School of Medicine (New Haven, CT) and was a MRC postdoctoral fellow at the Ontario Cancer Institute (Toronto, ON).
At the Ontario Cancer Institute, he was involved in the discovery of the human T Cell Receptor.
Dr. Toyonaga received a Ph.D.
in physical organic chemistry from the University of Toronto (St. George Campus, Toronto, ON).
Former positions of Barry E. Toyonaga
| Companies | Position | End |
|---|---|---|
Traversa Therapeutics, Inc.
 Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Corporate Officer/Principal | 19/12/2012 |
Ventana Capital Management LLC
 Ventana Capital Management LLC Investment ManagersFinance Ventana Capital Management LLC (Ventana Capital) is a venture capital firm founded in 1984 by Tom O. Gephart. The firm is headquartered in Rancho Santa Margarita, California. | Private Equity Investor | 31/12/2008 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Corporate Officer/Principal | - |
Training of Barry E. Toyonaga
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Private companies | 3 |
|---|---|
Ventana Capital Management LLC
Ventana Capital Management LLC Investment ManagersFinance Ventana Capital Management LLC (Ventana Capital) is a venture capital firm founded in 1984 by Tom O. Gephart. The firm is headquartered in Rancho Santa Margarita, California. | Finance |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Commercial Services |
- Stock Market
- Insiders
- Barry E. Toyonaga
